<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>18-Fluoro-<z:chebi fb="0" ids="15866">deoxyglucose</z:chebi> <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography/computerised tomography (FDG PET/CT) is commonly used in the management of patients with <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and is recommended for both initial staging and response assessment after treatment in patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite the FDG avidity of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), FDG PET/CT is not yet applied in standard clinical practice for patients with FL </plain></SENT>
<SENT sid="2" pm="."><plain>However, FDG PET/CT is more accurate than conventional imaging for initial staging, often prompting significant management change, and allows noninvasive characterization to guide assessment of high-grade transformation </plain></SENT>
<SENT sid="3" pm="."><plain>For restaging, FDG PET/CT assists in distinguishing between scar tissue and viable <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in residual masses and a positive PET after induction treatment would seem to predict a shorter progression-free survival </plain></SENT>
</text></document>